Barr’s Rationale For Pliva Merger: Business Synergy, Biogenerics Leadership
Executive Summary
Barr is highlighting its complementary product portfolio and business model in its efforts to ward off competition from Actavis to acquire Pliva
You may also be interested in...
Generic Drugs Don’t Come Cheap: Teva Buys Barr For $7.46 Billion
Teva's $7.46 billion acquisition of Barr will create an unrivaled generics powerhouse and position the company as a leader in the industry's next untapped frontier: biosimilars
Generic Drugs Don’t Come Cheap: Teva Buys Barr For $7.46 Billion
Teva's $7.46 billion acquisition of Barr will create an unrivaled generics powerhouse and position the company as a leader in the industry's next untapped frontier: biosimilars
Barr Cuts Low-Volume Products In Post-Merger Rationalization
Barr is paring low-volume products from its portfolio and pipeline following the integration of Pliva's products and R&D programs